HCG Q2 FY27 Results: Revenue up 16% to ₹731.8 Crore, Adj. EBITDA up 17% to ₹142.5 Crore
HCG reported Q2 FY27 results with revenue up 16% YoY to ₹731.8 Crore and Adjusted EBITDA up 17% YoY to ₹142.5 Crore. Margins improved to 19.7%. The company added 146 beds in H1 FY27 and expanded advanced technology deployment. Growth was broad-based across regions, with international business up 54%.
The announcement includes detailed financial results for the quarter and half-year, highlighting significant revenue and profit growth, alongside strategic operational and technological developments. This provides substantial information for investors to assess the company's performance and future outlook.
The company reported strong year-on-year growth in revenue and Adjusted EBITDA, along with improved margins and significant operational and technological advancements. The expansion of capacity and introduction of new therapies indicate positive future prospects.
Healthcare Global Enterprises Limited (HCG) announced its unaudited financial results for the quarter and six months ended September 30, 2026, on November 5, 2026. The company reported a consolidated revenue of ₹7,318 million (₹731.8 Crore) for the second quarter of FY27, marking a 16% year-on-year growth. Adjusted EBITDA also saw a significant increase of 17% year-on-year, reaching ₹1,425 million (₹142.5 Crore), with margins improving to 19.7% from 19.2% in the same quarter last year.
Operational highlights for the quarter included a 9% year-on-year increase in volume and a 7% rise in Average Realization Per Patient (ARPP). The company added 146 operational beds in the first half of FY27, with 25 beds added in Q2 FY27 across Kenya, Kolkata, and Nagpur. HCG also operationalized advanced technology, including an MR-LINAC system at North Bengaluru, a LINAC in Africa, and a cardiac robotic surgery system at HMS Ahmedabad. Significant clinical advancements were made with the first CAR-T cell therapy performed at HCC Ahmedabad, and the introduction of robotic surgeries and precision diagnostics.
The South cluster led revenue growth with an 18% year-on-year increase, driven by ARPP growth and patient volumes. The West cluster reported a 10% year-on-year revenue growth, while the East cluster saw a substantial 23% year-on-year increase. International business revenue grew by 54% year-on-year.
For the first six months of FY27, total revenue stood at ₹14,100 million (₹1,410 Crore), a 15% increase year-on-year, and Adjusted EBITDA grew by 18% to ₹2,740 million (₹274 Crore), with margins at 19.7%. The company's net debt position as of September 30, 2026, was ₹5,751 million (₹575.1 Crore). HCG continues to focus on its strategic priorities, including capacity expansion, enhancing patient experience, and operational excellence, with a target of adding 1,000 beds by FY30.
What to do with a filing like this
Healthcare Global Enterprises Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Healthcare Global Enterprises Limited. Read the original for the full detail.